Myricetin enhance chemosensitivity of 5-fluorouracil on esophageal carcinoma in vitro and in vivo

Cancer Cell International

Guoqiang Zhao⁴  Shijie Zhang³  Wenqiao Zang⁴  Yuanyuan Wang⁴  Yuwen Du⁴  Wei Guo¹  Xiaonan Chen⁴  Jianfang Feng²  Lei Wang⁵ 

[1]Henan Academy of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450052, China

[2]Medical College of Henan University of Science and Technology, Luoyang 471003, China

[3]Department of Clinical Laboratory, The First Affiliated Hospital of Zhengzhou University, No.1, Jianshe Road, Zhengzhou 450052, China

[4]College of Basic Medical Sciences, Zhengzhou University, Zhengzhou 450001, China

[5]Department of Emergency, The First Affiliated Hospital of Zhengzhou University, No.1, Jianshe Road, Zhengzhou 450052, China

关键词: Chemosensitizer;    Esophageal carcinoma;    5-fluorouracil;    Myricetin;   

Others  :  1121681
DOI  :  10.1186/s12935-014-0071-2

 received in 2014-05-05, accepted in 2014-07-10,  发布年份 2014

【 摘 要 】

Background

Flavonoids are structurally heterogeneous, polyphenolic compounds present in high concentrations in fruits, vegetables, and other plant-derived foods. Currently, there is growing interest in the therapeutic applications of bioflavonoids for the treatment and prevention of diseases in humans. Myricetin is a naturally occurring flavonoid that is commonly found in tea, berries, fruits, vegetables, and medicinal herbs. Previous studies have shown that myricetin has antioxidant, anti-inflammatory and potent anticancer effects. It was interesting to investigate whether myricetin has the cooperative inhibitory effect combined with 5-fluorouracil on esophageal cancer cells.

Methods

EC9706 cells were treated with 5-fluorouracil combination with or without myricetin. Colony formation assays, CCK-8 assay and flow cytometry were used to evaluate the chemosensitization activity of myricetin combine with 5-fluorouracil on the cell growth and viability, cell proliferation and apoptosis in vitro. Western blot was engaged to detect changes of Survivin, Cyclin D, Bcl-2, Caspase-3 and P53 protein expression level, which were associated with cells proliferation and apoptosis. Nude mouse tumor xenograft model was built to assessed chemosensitization effect of myricetin combine with 5-fluorouracil in vivo.

Results

Compared with the 5-fluorouracil group without myricetin treatment, the groups treated with 5-fluorouracil combine with myricetin showed significantly suppressed cell survival fraction and proliferation, increased the cell apoptosis. Decreased Survivin, Cyclin D, Bcl-2, and increased Caspase-3, P53 expression level were aslo confirmed by western blot in 5-fluorouracil combine with myricetin groups in vitro. And in vivo assay, growth speed of tumor xenografts was significantly decreased in the mice treated with 5-fluorouracil + myricetin combiantion group.

Conclusions

The study demonstrated both in vitro and in vivo evidence that combination of myricetin with 5-fluorouracil chemotherapy can enhance tumor chemosensitivity of esophageal cancer EC9706 cells, and myricetin could be a potential chemosensitizer for esophageal cancer therapy.

【 授权许可】

   
2014 Wang et al.; licensee Springer

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Szumiło J: Epidemiology and risk factors of the esophageal squamous cell carcinoma. Pol Merkur Lekarski 2009, 26:82-85.
• [2]Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
• [3]Homs MY, Voest EE, Siersema PD: Emerging drugs for esophageal cancer. Expert Opin Emerg Drugs 2009, 14:329-339.
• [4]Wang LD, Zhou FY, Li XM, Sun LD, Song X, Jin Y, Li JM, Kong GQ, Qi H, Cui J, Zhang LQ, Yang JZ, Li JL, Li XC, Ren JL, Liu ZC, Gao WJ, Yuan L, Wei W, Zhang YR, Wang WP, Sheyhidin I, Li F, Chen BP, Ren SW, Liu B, Li D, Ku JW, Fan ZM, Zhou SL: Genome-wide association study of esophageal squamous cell carcinoma in Chinese subjects identifies susceptibility loci at PLCE1 and C20orf54. Nat Genet 2010, 42:759-763.
• [5]Campbell NP, Villaflor VM: Neoadjuvant treatment of esophageal cancer. World J Gastroenterol 2010, 16:3793-3803.
• [6]Neuner G, Patel A, Suntharalingam M: Chemoradiotherapy for esophageal cancer. Gastrointest Cancer Res 2009, 3:57-65.
• [7]Shah MA, Kelsen DP: Combined modality therapy of esophageal cancer: changes in the standard of care? Ann Surg Oncol 2004, 11:641-643.
• [8]Kato H, Nakajima M: Treatments for esophageal cancer: a review. Gen Thorac Cardiovasc Surg 2013, 61:330-335.
• [9]Nabeya Y, Ochiai T: Chemotherapy for esophageal cancer. Gan To Kagaku Ryoho 2003, 30:1873-1880.
• [10]Wang J, Yang ZR, Dong WG, Zhang JX, Guo XF, Song J, Qiu S: Cooperative inhibitory effect of sinomenine combined with 5-fluorouracil on esophageal carcinoma. World J Gastroenterol 2013, 19:8292-8300.
• [11]Guo XF, Zhu XF, Zhong GS, Deng BG, Gao ZT, Wang H: Lapatinib, a dual inhibitor of EGFR and HER2, has synergistic effects with 5-fluorouracil on esophageal carcinoma. Oncol Rep 2012, 27:1639-1645.
• [12]Tian F, Zhang C, Tian W, Jiang Y, Zhang X: Comparison of the effect of p65 siRNA and curcumin in promoting apoptosis in esophageal squamous cell carcinoma cells and in nude mice. Oncol Rep 2012, 28:232-240.
• [13]Hartojo W, Silvers AL, Thomas DG, Seder CW, Lin L, Rao H, Wang Z, Greenson JK, Giordano TJ, Orringer MB, Rehemtulla A, Bhojani MS, Beer DG, Chang AC: Curcumin promotes apoptosis, increases chemosensitivity, and inhibits nuclear factor kappaB in esophageal adenocarcinoma. Transl Oncol 2010, 3:99-108.
• [14]Gao Y, Hu N, Han XY, Ding T, Giffen C, Goldstein AM, Taylor PR: Risk factors for esophageal and gastric cancers in Shanxi Province, China: a case-control study. Cancer Epidemiol 2011, 35:e91-e99.
• [15]Oze I, Matsuo K, Hosono S, Ito H, Kawase T, Watanabe M, Suzuki T, Hatooka S, Yatabe Y, Hasegawa Y, Shinoda M, Tajima K, Tanaka H: Comparison between self-reported facial flushing after alcohol consumption and ALDH2 Glu504Lys polymorphism for risk of upper aerodigestive tract cancer in a Japanese population. Cancer Sci 2010, 101:1875-1880.
• [16]Veugelers PJ, Porter GA, Guernsey DL, Casson AG: Obesity and lifestyle risk factors for gastroesophageal reflux disease, Barrett esophagus and esophageal adenocarcinoma. Dis Esophagus 2006, 19:321-328.
• [17]Mayne ST, Risch HA, Dubrow R, Chow WH, Gammon MD, Vaughan TL, Farrow DC, Schoenberg JB, Stanford JL, Ahsan H, West AB, Rotterdam H, Blot WJ, Fraumeni JF Jr: Nutrient intake and risk of subtypes of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev 2001, 10:1055-1062.
• [18]Ong KC, Khoo HE: Biological effects of myricetin. Gen Pharmacol 1997, 29:121-126.
• [19]Ross JA, Kasum CM: Dietary flavonoids: bioavailability, metabolic effects, and safety. Annu Rev Nutr 2002, 22:19-34.
• [20]Weng CJ, Yen GC: Flavonoids, a ubiquitous dietary phenolic subclass, exert extensive in vitro anti-invasive and in vivo anti-metastatic activities. Cancer Metastasis Rev 2012, 31:323-351.
• [21]Sun F, Zheng XY, Ye J, Wu TT, Wang JL, Chen W: Potential anticancer activity of myricetin in human T24 bladder cancer cells both in vitro and in vivo. Nutr Cancer 2012, 64:599-606.
• [22]Tai IT, Dai M, Owen DA, Chen LB: Genome-wide expression analysis of therapy-resistant tumors reveals SPARC as a novel target for cancer therapy. J Clin Invest 2005, 115:1492-1502.
• [23]O'Neill OM, Johnston BT, Coleman HG: Achalasia: a review of clinical diagnosis, epidemiology, treatment and outcomes. World J Gastroenterol 2013, 19:5806-5812.
• [24]Zhang Y: Epidemiology of esophageal cancer. World J Gastroenterol 2013, 19:5598-5606.
• [25]Anderson SE, Minsky BD, Bains M, Kelsen DP, Ilson DH: Combined modality therapy in esophageal cancer: the Memorial experience. Semin Surg Oncol 2003, 21:228-232.
• [26]Koyama H, Iwata H, Kuwabara Y, Iwase H, Kobayashi S, Fujii Y: Gelatinolytic activity of matrix metalloproteinase-2 and -9 in oesophageal carcinoma; a study using in situ zymography. Eur J Cancer 2000, 36:2164-2170.
• [27]Pera M, Gallego R, Montagut C, Martín-Richard M, Iglesias M, Conill C, Reig A, Balagué C, Pétriz L, Momblan D, Bellmunt J, Maurel J: Phase II trial of preoperative chemoradiotherapy with oxaliplatin, cisplatin, and 5-FU in locally advanced esophageal and gastric cancer. Ann Oncol 2012, 23:664-670.
• [28]Chen R, Hollborn M, Grosche A, Reichenbach A, Wiedemann P, Bringmann A, Kohen L: Effects of the vegetable polyphenols epigallocatechin-3-gallate, luteolin, apigenin, myricetin, quercetin, and cyanidin in primary cultures of human retinal pigment epithelial cells. Mol Vis 2014, 20:242-258.
• [29]Zhang S, Wang L, Liu H, Zhao G, Ming L: Enhancement of recombinant myricetin on the radiosensitivity of lung cancer A549 and H1299 cells. Diagn Pathol 2014, 9:68. BioMed Central Full Text
• [30]Massagué J: G1 cell-cycle control and cancer. Nature 2004, 432:298-306.
• [31]Schwartz GK, Shah MA: Targeting the cell cycle: a new approach to cancer therapy. J Clin Oncol 2005, 23:9408-9421.
• [32]Malumbres M, Barbacid M: Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer 2009, 9:153-166.
• [33]Konstantinidou AE, Korkolopoulou P, Patsouris E: Apoptotic markers for tumor recurrence: a minireview. Apoptosis 2002, 7:461-470.
• [34]Yano M, Inoue M, Shiozaki H: Preoperative concurrent chemotherapy and radiation therapy followed by surgery for esophageal cancer. Ann Thorac Cardiovasc Surg 2002, 8:123-130.
• [35]Ferreira VA, Czeczko NG, Ribas-Filho JM, Malafaia O, Ribas CA, Gomes CS, Cunha RM, Cuenca RM: CD-34 and CASPASE-3 biomarkers expression in esophageal epidermoid carcinoma. Rev Col Bras Cir 2009, 36:35-41.
• [36]Ikeguchi M, Yamaguchi K, Kaibara N: Survivin gene expression positively correlates with proliferative activity of cancer cells in esophageal cancer. Tumour Biol 2003, 24:40-45.
• [37]Altieri DC: Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene 2003, 22:8581-8589.
• [38]Itaya M, Yoshimoto J, Kojima K, Kawasaki S: Immunohistochemistry of p53, Bcl-2, and Ki-67 as predictors of chemosensitivity. Methods Mol Med 2005, 110:213-227.
• [39]Hsia JY, Chen CY, Hsu CP, Shai SE, Yang SS, Chuang CY, Wang PY, Chen JT: Expression of apoptosis-regulating proteins p53, Bcl-2, and Bax in primary resected esophageal squamous cell carcinoma. Neoplasma 2001, 48:483-488.
• [40]Kigawa J, Sato S, Shimada M, Takahashi M, Itamochi H, Kanamori Y, Terakawa N: p53 gene status and chemosensitivity in ovarian cancer. Hum Cell 2001, 14:165-171.